Sanofi: Zaltrap obtains approval in Europe

BUY, Fair Value EUR84 (+21%)

News published on February Tuesday 5, 2013
Share on
Although this comes as no a major surprise following the positive recommendation received last November, Sanofi has announced that the European Commission has approved Zaltrap (aflibercept) this morning. The compound is an anti-angiogenesis compound developed in partnership with Regeneron and indicated in second-line treatment of colorectal cancer in combination with chemotherapy.

Full report available to subscribers
Please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities